Healthcare Market Research Company in France

BioNixus is a leading healthcare market research company in France, delivering French-language HCP surveys, KOL mapping, and payer landscape research aligned with ANSM, HAS, and Assurance Maladie requirements. BioNixus combines primary research depth with physician access across major French CHUs (AP-HP Paris, HCL Lyon, APHM Marseille, CHU Bordeaux, CHU Toulouse) and specialist community networks.

A healthcare market research company in France designs and executes studies covering physician prescribing behaviour, HAS SMR/ASMR benefit assessment dynamics, CEPS payer and pricing intelligence, patient journeys, KOL influence mapping, Assurance Maladie formulary access, and GHT hospital formulary research — for pharmaceutical, biotech, and medical device companies launching or growing in the French market.

France operates a mandatory two-dimensional HTA system where HAS SMR (reimbursability) and ASMR (added therapeutic value, grades I–V) jointly determine both access and CEPS price negotiation leverage — a structure found nowhere else in Europe. Assurance Maladie provides universal reimbursement coverage, while complémentaires santé (mutuelles, prévoyance) cover approximately 95% of the population for additional costs. France's 18 metropolitan regions operate via GHTs (groupements hospitaliers de territoire) making shared hospital formulary decisions. This combination creates a uniquely complex multi-layer access landscape requiring specialist French-specific research.

BioNixus covers oncology (including Cancéropôle and CLCC networks, Institut Curie, IGR), immunology and biologics (including biosimilar substitution dynamics under Assurance Maladie policies), cardiovascular, diabetes and metabolic, rare disease (AAP — autorisation d'accès précoce, and early access programs), respiratory, infectious disease, neurology, medical devices, and consumer health across the French market.

Yes. BioNixus maintains physician and specialist networks across major French CHUs including AP-HP Paris (Salpêtrière, Bichat, Lariboisière, Cochin, Saint-Louis), HCL Lyon (Herriot, Lyon-Sud, Croix-Rousse), APHM Marseille (La Timone, Nord), CHU Bordeaux, and CHU Toulouse (Rangueil, Purpan). For scarce specialties such as oncology or rare disease, BioNixus recruits through Cancéropôle research networks, Institut Curie, Institut Gustave Roussy (IGR), and CLCC (Centres de Lutte Contre le Cancer) networks across France. All recruitment and interviews are conducted in French.

Focused HCP surveys typically complete in 3–4 weeks. Full mixed-method programmes including HAS payer depth interviews, CEPS intelligence research, and advisory board modules typically run 6–10 weeks depending on therapy area and respondent scarcity. Oncology and rare disease KOL programmes with multi-CHU recruitment across France may require extended planning timelines.

Yes. BioNixus designs and executes French patient research in compliance with CNIL (Commission nationale de l'informatique et des libertés) requirements and GDPR. All patient and caregiver research involves documented informed consent, pseudonymised or de-identified reporting, and secure data handling under French data privacy law. Research protocols are designed to meet CNIL guidelines for health data processing.

Yes. French modules can run with comparable cells across the EU5 (Germany, UK, Spain, Italy), and beyond to the USA, Canada, Japan, Saudi Arabia, and UAE — using consistent instruments for global portfolio committees managing multi-market access strategy from one research partner.